Elavil, the brand-name version of amitriptyline, was discontinued for business reasons, not because of safety or effectiveness concerns. The FDA formally confirmed this, stating it found “no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.” The drug itself never went away. Generic amitriptyline remains widely available from multiple manufacturers including Sandoz, Mylan, Teva, and Sun Pharma.
Why the Brand Name Disappeared
When a brand-name drug loses patent protection, generic versions flood the market at a fraction of the price. For the original manufacturer, continuing to produce the branded version becomes a losing business proposition. That’s what happened with Elavil. The FDA placed it on the “Discontinued Drug Product List,” a category specifically for drugs pulled from the market for reasons other than safety or effectiveness. This is a common lifecycle for brand-name medications once generics take over.
All brand-name versions of amitriptyline, including both Elavil and another brand called Endep, have been discontinued. But the generic market is active, and as of early 2026, amitriptyline is not listed on the FDA’s drug shortage database.
Why Doctors Prescribe It Less Often
While Elavil wasn’t pulled for safety reasons, there’s a separate and important reason you hear less about amitriptyline today: newer antidepressants have largely replaced it for treating depression. SSRIs cause significantly fewer side effects while delivering comparable results. In one head-to-head trial, 75% of patients on amitriptyline reported adverse events compared to just 20% on the SSRI citalopram, yet the two drugs reduced depression scores by similar amounts (68% versus 72%).
That shift in prescribing habits reduced demand for the brand-name product, which likely accelerated the business decision to discontinue Elavil.
The Side Effect Problem
Amitriptyline belongs to an older class of antidepressants called tricyclics, which affect multiple chemical systems in the body at once. That broad activity creates a heavy side effect burden. A meta-analysis found that roughly one in three patients experiences side effects related to the drug’s anticholinergic activity, meaning the effects it has on the nervous system beyond its intended target.
The most common issues, and how much more likely they are compared to a placebo:
- Dry mouth: about 12 times more likely, affecting around half of patients in clinical trials
- Drowsiness and sedation: 3 to 5 times more likely, reported by roughly 35% of patients
- Fatigue: nearly 3 times more likely than placebo
- Dizziness, blurred vision, insomnia, and sexual dysfunction: all reported at meaningful rates
For many people, these side effects made the drug difficult to tolerate long-term, especially when SSRIs offered a much lighter burden.
Overdose Risk With Tricyclics
One of the more serious concerns with amitriptyline, and tricyclic antidepressants in general, is how dangerous they are in overdose. Life-threatening toxicity can occur at doses as low as 10 mg per kilogram of body weight. For a 150-pound person, that could mean ingesting as few as 15 to 20 tablets of a common dose.
Overdose primarily affects the heart. It can cause dangerous changes in heart rhythm, drops in blood pressure, seizures, and coma. In one study of overdose patients, 34% of those who developed a specific cardiac abnormality experienced seizures, and 14% developed life-threatening heart rhythm problems. Because amitriptyline was prescribed to people with depression, a population at elevated risk for self-harm, this narrow margin between a therapeutic dose and a lethal dose was a serious clinical concern. SSRIs, by contrast, are far less toxic in overdose, which made them a safer choice for many patients.
Amitriptyline Is Still Prescribed Today
Despite losing ground as a first-line antidepressant, generic amitriptyline remains in regular use. Doctors prescribe it for chronic pain conditions, migraine prevention, fibromyalgia, and insomnia, often at lower doses than those used for depression. At these lower doses, side effects tend to be milder and more manageable.
The current FDA label does carry a boxed warning about the risk of suicidal thoughts, particularly in children and young adults starting antidepressant treatment. The drug is not approved for pediatric use. Prescribers are advised to write prescriptions for the smallest practical quantity of tablets to reduce overdose risk. These warnings apply to the generic version just as they did to brand-name Elavil, since the medication itself is identical.
If you’re currently taking amitriptyline or considering it, the disappearance of the Elavil brand name changes nothing about the drug’s availability or your prescription. You’re getting the same molecule, manufactured to the same FDA standards, at a lower cost.